AstraZeneca Pharma India reports 129% rise in Q4 PAT at ₹39.47 crore, operating revenue up 35%

Revenue from operations rose 35% to ₹383.19 crore during the quarter while total revenue increased 34% to ₹391.86 crore.

For the full fiscal year 2024, the firm reported a 63% rise in its net profit at ₹161.51 crore. Revenue from operations rose 29% to ₹1,296 crore during the year while total revenue grew 30% to ₹1,330 crore. The firm’s earnings per share (EPS) for the financial year stood at ₹64.6, registering a growth of 63% YoY.

AstraZeneca said on a global level, the firm aspires to deliver $80 billion in total revenue by 2030. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade, achieve industry-leading growth and aim to be carbon negative, the company stated in a release.

The board of directors of the firm recommended a final dividend of ₹24 per equity share for the financial year 2024.

Sanjeev Panchal, country president and managing director of AstraZeneca India said the fiscal year 2024 was one of the strongest ones for the firm in the country. “AstraZeneca India products sales for first time crossed ₹1,000 crore mark, delivering a total revenue of almost ₹1,300 crore, with growth of 29% this year,” he said.

AstraZeneca is a biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas — oncology, cardiovascular, renal and metabolism and respiratory and rare diseases. The company operates in over 100 countries and is headquartered in Bengaluru, Karnataka.

Shares of the company were trading nearly 14% higher on Tuesday. The stock has gained nearly 97% in the last one year.